
Johan W R Nortier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8401103/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. Journal of Clinical Oncology, 2022, 40, 2934-2945.	1.6	6
2	Perceptions of Japanese and Dutch women with early breast cancer about monitoring their quality of life. Journal of Psychosocial Oncology, 2021, , 1-14.	1.2	0
3	Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications, 2020, 11, 3083.	12.8	173
4	<p>Illness Perceptions and Quality of Life in Patients with Non-Small-Cell Lung Cancer: A 3-Month Follow-Up Pilot Study</p> . Patient Related Outcome Measures, 2020, Volume 11, 67-71.	1.2	6
5	Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Research, 2019, 21, 97.	5.0	6
6	Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer. Oncologist, 2019, 24, e467-e474.	3.7	26
7	Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy. Supportive Care in Cancer, 2019, 27, 1919-1925.	2.2	11
8	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). Journal of the National Cancer Institute, 2018, 110, 40-48.	6.3	138
9	Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. European Journal of Cancer, 2018, 95, 59-67.	2.8	7
10	Patient-reported outcome assessment and objective evaluation of chemotherapy-induced alopecia. European Journal of Oncology Nursing, 2018, 33, 49-55.	2.1	9
11	Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer. Breast Cancer Research and Treatment, 2018, 168, 413-420.	2.5	5
12	Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1211-1220.	10.7	45
13	Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Supportive Care in Cancer, 2016, 24, 2735-2741.	2.2	22
14	The effects of illness beliefs and chemotherapy impact on quality of life in Japanese and Dutch patients with breast or lung cancer. Chinese Clinical Oncology, 2016, 5, 3.	1.2	16
15	Intensive care admission of cancer patients: a comparative analysis. Cancer Medicine, 2015, 4, 966-976.	2.8	70
16	The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer, 2015, 15, 652.	2.6	170
17	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Molecular Cancer Therapeutics, 2015, 14, 821-827.	4.1	49
18	Randomised study of tegafur–uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer — TLC study. Journal of Geriatric Oncology, 2015, 6, 307-315.	1.0	15

#	Article	IF	CITATIONS
19	Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – A phase II trial. European Journal of Cancer, 2014, 50, 2190-2200.	2.8	67
20	Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?. Journal of Clinical Medicine, 2013, 2, 188-200.	2.4	3
21	Routine Monitoring of Quality of Life for Patients with Breast Cancer: An Acceptability and Field Test. Journal of Psychosocial Oncology, 2012, 30, 239-259.	1.2	11